Real-world data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment for chronic Hepatitis C really effective?

Basit Öğe Kaydı
dc.contributor.authorDemirtürk, Neşe
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorÇelik, İlhami
dc.contributor.authorMistik, Reşit
dc.contributor.authorAkhan, Sıla
dc.contributor.authorBarut, Şener
dc.contributor.authorUral, Onur
dc.contributor.authorBatırel, Ayşe
dc.contributor.authorŞimsek, Funda
dc.contributor.authorErsöz, Gülden
dc.contributor.authorİnan, Dilara
dc.contributor.authorKınıklı, Sami
dc.contributor.authorTürker, Nesrin
dc.contributor.authorBilgin, Hüseyin
dc.contributor.authorGürbüz, Yunus
dc.contributor.authorTülek, Necla
dc.contributor.authorTarakçı, Hüseyin
dc.contributor.authorYıldız, Orhan
dc.contributor.authorTürkoğlu, Emine
dc.contributor.authorGüzel, Deniz Kamalak
dc.contributor.authorŞimsek, Sümeyra
dc.contributor.authorTuna, Nazan
dc.contributor.authorDemir, Nazlım Aktuğ
dc.contributor.authorÇağatay, Atahan
dc.contributor.authorÇetinkaya, Rıza Aytaç
dc.contributor.authorKarakeçili, Faruk
dc.contributor.authorHakyemez, İsmail Necati
dc.contributor.authorErtem, Günay Tuncer
dc.contributor.authorÖrmen, Bahar
dc.contributor.authorKorkmaz, Pınar
dc.contributor.authorSili, Uluhan
dc.contributor.authorKuruüzüm, Ziya
dc.contributor.authorŞener, Alper
dc.contributor.authorÖzel, Selcan Arslan
dc.contributor.authorÖztürk, Sinan
dc.contributor.authorSüer, Kaya
dc.contributor.authorÇelen, Mustafa Kemal
dc.contributor.authorKonya, Petek
dc.contributor.authorAsan, Ali
dc.contributor.authorSaltoğlu, Neşe
dc.contributor.authorDoğan, Nurhan
dc.date.accessioned2022-08-26T11:49:04Z
dc.date.available2022-08-26T11:49:04Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalıen_US
dc.descriptionWOS:000648816400007
dc.descriptionPMID: 33960939
dc.description.abstractBackground: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. Methods: Data from patients with chronic hepatitis C treated with SOF/LDV +/- RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed. Results: A total of 552 patients were included in the study. The mean age of the patients was 51.28 +/- 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV +/- RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect. Conclusion: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV +/- RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.en_US
dc.identifier.citationDemirtürk, N., Aygen, B., Çelik, İ., Mıstık, R., Akhan, S. ve Barut, S. (2021). Real-world data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment for chronic Hepatitis C really effective?. Turkish Journal of Gastroenterology, 32(2), 155-163. https://doi.org/10.5152/tjg.2020.19569en_US
dc.identifier.doi10.5152/tjg.2020.19569
dc.identifier.endpage163en_US
dc.identifier.issn2148-5607
dc.identifier.issue2en_US
dc.identifier.pmid33960939
dc.identifier.scopus2-s2.0-85106497950
dc.identifier.scopusqualityQ3
dc.identifier.startpage155en_US
dc.identifier.trdizinid511870
dc.identifier.urihttps://www.turkjgastroenterol.org/en/real-world-data-from-turkey-is-sofosbuvir-ledipasvir-with-or-without-ribavirin-treatment-for-chronic-hepatitis-c-really-effective-136736
dc.identifier.urihttps://hdl.handle.net/11468/10264
dc.identifier.volume32en_US
dc.identifier.wosWOS:000648816400007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorÇelen, Mustafa Kemal
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic hepatitis Cen_US
dc.subjectSofosbuviren_US
dc.subjectLedipasviren_US
dc.subjectSustained virological responseen_US
dc.subjectGenotypeen_US
dc.subjectReal-world dataen_US
dc.titleReal-world data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment for chronic Hepatitis C really effective?en_US
dc.titleReal-world data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment for chronic Hepatitis C really effective?
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Real-world data from Turkey Is sofosbuvir-ledipasvir with or without ribavirin treatment for chronic Hepatitis C really effective.pdf
Boyut:
280.58 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu